On March 8, 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana (Press release, Syros Pharmaceuticals, MAR 8, 2022, View Source [SID1234609668]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The online-only e-poster will include data that show Syros’ orally available, selective CDK12 inhibitor has potent single agent activity in vitro and in vivo in multiple cancer models as well as enhanced antitumor effect in combination with DNA damaging agents. These data support Syros’ plans to nominate a development candidate from its CDK12 inhibitor program in the second half of 2022.

Details of the e-poster presentation are as follows:

Presentation Title: An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity
Session Title: Molecular Targets
Session Category: Experimental and Molecular Therapeutics
Abstract Number: 5393

The abstract is now available on the AACR (Free AACR Whitepaper) conference website: View Source The e-poster will become available on the AACR (Free AACR Whitepaper) conference website at 1:00 p.m. ET on Friday, April 8th.